Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 21.31 percent increase over losses of $(0.61) per share
Kalaris lost less money per share than experts thought it would, and it's also losing less money than it did last year. When a company is improving how much it loses, that's a sign things might be getting better.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.